{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:17Z","timestamp":1790286917945,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T00:00:00Z","timestamp":1358812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Nilotinib and dasatinib are second\u2010generation tyrosine kinase inhibitors approved for the treatment of chronic myeloid leukemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>). In clinical trials, they have both been reported to cause rash in a significant number of patients, but its incidence varies significantly and has not been characterized clinically or histologically. The aim of this study was to determine the incidence of rash with nilotinib and dasatinib, and to provide a clinical and histopathological description of the rash.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a meta\u2010analysis of clinical trials evaluating nilotinib and dasatinib to determine and compare the incidence of rash with these medications. Additionally, we performed a retrospective chart review to analyze the clinical presentation and histology of patients presenting with rash.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The incidence of all\u2010grade (grade 1\u20134) rash with nilotinib was 34.3% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 27.9\u201341.3), higher (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.017) than with dasatinib (23.3%; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 18.8\u201328.6). Similarly, the incidence of high\u2010grade rash with nilotinib (2.6%; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 2.1\u20133.4) was higher (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.002) than with dasatinib (1.1%; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>, 0.8\u20131.6). The clinical presentation often consisted of a pruritic, perifollicular hyperkeratotic, occasionally erythematous papular rash affecting most areas of the body, depending on the severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Both nilotinib and dasatinib are associated with rash in a significant number of patients. Further studies to prevent and treat rash with nilotinib and dasatinib are required to improve patient quality of life, adherence with therapy and oncologic outcome.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12052","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T12:29:28Z","timestamp":1355488168000},"page":"142-150","source":"Crossref","is-referenced-by-count":35,"title":["Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta\u2010analysis and clinical characterization"],"prefix":"10.1111","volume":"90","author":[{"given":"Aaron M.","family":"Drucker","sequence":"first","affiliation":[{"name":"Division of Dermatology Department of Medicine University of Toronto"},{"name":"Dermatology Service Department of Medicine Memorial Sloan\u2010Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Stony Brook University Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus J.","family":"Busam","sequence":"additional","affiliation":[{"name":"Dermatopathology Service Department of Pathology Memorial Sloan\u2010Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellin","family":"Berman","sequence":"additional","affiliation":[{"name":"Leukemia Service Department of Medicine Memorial Sloan\u2010Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Amitay\u2010Laish","sequence":"additional","affiliation":[{"name":"Department of Dermatology Rabin Medical Center Beilinson Hospital Petach Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Dermatology Service Department of Medicine Memorial Sloan\u2010Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083196"},{"key":"e_1_2_6_3_1","first-page":"454","article-title":"Efficacy of frontline nilotinib therapy in patients (pts) with newly diagnosed philadelphia chromosome (ph)\u2010positive chronic myeloid leukemia in early chronic phase (CML\u2010CP)","volume":"118","author":"Quintas\u2010Cardama A","year":"2011","journal-title":"ASH Ann Meeting Abstr"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0366"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0327-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26249"},{"key":"e_1_2_6_11_1","first-page":"2703","article-title":"A phase II study of nilotinib, a novel inhibitor of c\u2010kit, PDGFR, and bcr\u2010abl, administered to patients with systemic mastocytosis","volume":"108","author":"Hochhaus A","year":"2006","journal-title":"ASH Ann Meeting Abstr"},{"key":"e_1_2_6_12_1","first-page":"4437","article-title":"A Canadian expanded access trial of oral nilotinib in adult patients with imatinib\u2010resistant or \u2010intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase","volume":"118","author":"Delage R","year":"2011","journal-title":"ASH Ann Meeting Abstr"},{"key":"e_1_2_6_13_1","first-page":"4912","article-title":"A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosiniphilic syndrome (HES)","volume":"108","author":"le Coutre P","year":"2006","journal-title":"ASH Ann Meeting Abstr"},{"key":"e_1_2_6_14_1","first-page":"2771","article-title":"Effect of nilotinib (NIL) on molecular response in chronic myelogenous leukemia \u2013 chronic phase (CML\u2010CP) patients (pts) with a suboptimal molecular response to imatinib (IM)\u2010ENABL study update","volume":"118","author":"Ailawadhi S","year":"2011","journal-title":"ASH Ann Meeting Abstr"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26120"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0070"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1071"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.01.006"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25766"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2879"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5474"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011452"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21615"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181cee36e"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0260-2"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0288"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2009.11.008"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-105627"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.10.3.12367"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12052","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:34:25Z","timestamp":1700652865000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,22]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/ejh.12052"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12052","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,22]]}}}